Peter joined the Group in 2015 as Head of Life Sciences & Biosciences, with over 20 years’ experience in this sector, and became Chief Operating Officer in 2018. He is responsible for a number of the life science portfolio investments including Locate Bio, MyHealthChecked plc, Sense Biodetection, Axis Spine Technologies and Medovate and in July 2020 he oversaw the successful exit of The Native Antigen Company.

Peter is the champion of several of our key initiatives and working groups as well as heading up the VCT and EIS divisions of Mercia and is a member of:

Mercia Responsible Investment Committee – a Group-wide team committed to delivering the ESG strategy across the business.

Mercia O2 Committee – offering the benefits of diverse opinions, ideas and points of view.

Mercia Knowledge Committee – a Group wide Information and Data Development team which Peter Chairs.

Previous experience

Peter has been involved with a number of turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss-making business where, as managing director, sales quadrupled within three years and the business was subsequently sold to a private equity backed business and Diagnostic World, a fast-growing diagnostic provider to the NHS.